Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
140
resultados
Última actualización
23/01/2026 [07:29:00]
Resultados 125 a 140 de 140
Resumen de: CN121015915A
The present application relates to regenerating functional neurons for the treatment of neurological disorders. The present document provides methods and materials involved in the treatment of mammals having a cranial nerve disorder, such as Alzheimer's disease (e.g., Alzheimer's disease). For example, methods and materials are provided for administering a composition comprising an exogenous nucleic acid encoding a NeuroD1 polypeptide to a mammal suffering from a cranial nerve disorder.
Resumen de: CN121023005A
The invention provides an application of miRNA-532-5p (micro Ribonucleic Acid-532-5p) in a Parkinson's disease treatment and prognosis target drug. In the invention, firstly, it is verified that after overexpression of miRNA-532-5p, the athletic ability of mice is obviously recovered, and the TH content of striatum and nigra is obviously increased compared with that of MPTP group mice; secondly, after the miRNA-532-5p is over-expressed, the mRNA level of an inflammatory factor is obviously reduced, and the mRNA level of an anti-inflammatory factor is obviously increased; and finally, after the miRNA-532-5p is over-expressed, the content of serum inflammatory factors is obviously reduced, and the content of anti-inflammatory factors is obviously increased. In conclusion, the miRNA-532-5p simulant can enhance the function of the miRNA-532-5p, so that the neuroinflammation is relieved, the condition of the Parkinson's disease is relieved, and a new strategy is provided for clinical treatment of the Parkinson's disease.
Resumen de: AU2023449890A1
Opicapone for use as adjunctive therapy to preparations of levodopa and a DOPA decarboxylase inhibitor (DDCI) in the treatment of Parkinson's disease; characterised in that a patient with Parkinson's disease is treatable with preparations of levodopa and a DDCI without clinically diagnosed motor complications.
Resumen de: US2025361292A1
Provide herein are methods of treating human patients with familial Alzheimer's disease that result in delayed in symptom onset and/or slowed cognitive decline by administering a humanized monoclonal anti-amyloid beta (Aβ) antibody.
Resumen de: US2025361252A1
The present invention relates to a compound of formula (I), which is a phosphate ester of apomorphine, or a pharmaceutically acceptable salt thereof. The apomorphine phosphate ester according to the invention exhibits remarkably advantageous properties as a therapeutic, including a favorable tolerability, an improved side effect profile, particularly a reduced occurrence of skin nodule formation and panniculitis when administered subcutaneously, as well as pharmacokinetic and metabolic properties rendering it particularly well-suited as an apomorphine prodrug. The invention further relates to the compound of formula (I) for use as a medicament, particularly for use in the treatment of Parkinson's disease.
Resumen de: US2025361237A1
The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for treating diseases, such as autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, Alzheimer's disease, Parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 40 to 146; examples 1 to 63; compounds 1 to 248; tables 1 to 3). Preferred compounds are e.g. 1,4-dihydrobenzodpyrazolo3,4-f1,3diazepine derivatives and related compounds. An exemplary compound is e.g. 5-(2,6-difluorophenyl)-8-methoxy-1,4-dihydrobenzodpyrazolo3,4-f1,3diazepine (example 49). (Formula (II):
Resumen de: US2025360121A1
A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.
Resumen de: WO2025243901A1
Provided is an injection preparation for the treatment of Parkinson's disease or restless legs syndrome, the injection preparation comprising microparticles each containing a free dopamine receptor agonist and a biodegradable polymer. The volume average particle diameter D50 of the microparticles is 50 μm or less, and the concentration of the dopamine receptor agonist in plasma of a subject to which the injection preparation has been administered is retained for 1 month or longer.
Resumen de: WO2025245500A1
The invention described herein provides eIF2B agonist (e.g., COMPOUND 1 ) and uses thereof for treatment of diseases, especially neurodegenerative diseases, including vanishing white matter (VWM), Huntington's disease (HD), Charcot Marie Tooth syndrome (CMT), and Amyotropic Lateral Sclerosis (ALS).
Resumen de: AU2024250257A1
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Resumen de: WO2025243064A1
The main problem with treating Alzheimer' s is that there is no certain medicine for its treatment, or that there is medical resistance to it in the patient's body. By using the WJ-MSCs exosomes from the steam cells grade, the exosomes are extracted with the ultracentrifuge method and confirmed in the size of SEM and TEM exosomes in the range of less than 100nm. then the mir-299-5p is transfected to the cell WJ- MSCs, with the help of a vector, and the exosomes are then extracted, gathered, and formulated. Since the vesicles are under 100 nanometers (exo som es) and could enter the cell by passing the brain blood barrier, what is inside them is easily transferred into the neuronic cell and treats them. Also, it decreases the drug resistance in the body, and the existence of the mir-299-5p is targeted, has pharmaceutical effects, and recovers the neuronic cells that were injured.
Resumen de: CN121003613A
The invention relates to application of rubimaillin in preparation of a medicine for preventing and/or treating inflammatory diseases. It is found for the first time that rubimaillin can block inflammasome assembly and inhibit pyroptosis by being directly combined with NLRP3, and then the rubimaillin plays a remarkable curative effect in gout, sepsis and Alzheimer's disease, and a new thought is provided for new use of clinical old drugs and development of natural drugs.
Resumen de: CN121003676A
The traditional Chinese medicine formula comprises the following components in parts by mass: 100 parts of fructus alpiniae oxyphyllae, 100 parts of ramulus uncariae cum uncis, 100 parts of rhizoma nardostachyos, 100 parts of radix paeoniae alba, 70 parts of radix achyranthis bidentatae, 70 parts of xylaria nigripes, 70 parts of polygala japonica, 70 parts of conic gymnadenia tuber, 70 parts of herba cistanche, 70 g of radix scutellariae, 40 parts of scorpion and 40 parts of sea snake. The traditional Chinese medicine composition is prepared on the basis of the traditional Chinese medicine compatibility theory, treats both symptoms and root causes and has good prevention and treatment effects on Parkinson's disease through experimental verification.
Resumen de: CN121003643A
The invention belongs to the field of medicines for inhibiting Alzheimer's disease, and particularly relates to safflower seed oil for inhibiting Alzheimer's disease and a preparation method thereof. The invention specifically discloses an optimized moderate refining technology of safflower seed oil, and verification of a benign intervention effect of the optimized moderate refining technology on AD disease progression. Compared with the classic refining technology, the moderate refining can effectively reduce the loss of key fatty acid linoleic acid in the safflower seed oil and effectively improve the retention rate of trace accompanying substances such as sterol and vitamin E, and is superior to the traditional refining technology. The safflower seed oil obtained by moderate refining can effectively inhibit the progress of a double-transgenic Alzheimer's mouse in a multi-target and multi-mechanism manner, especially decrease the deposition amount of beta amyloid protein in brain tissues, increase the number of Nissl bodies in a cortex region of the brain tissues, and lower the peroxidation index in the brain tissues and serum, so as to inhibit the disease progression of the double-transgenic Alzheimer's mouse in a multi-target and multi-mechanism manner. The safflower seed oil obtained by moderate refining can be used for clinical treatment and adjuvant therapy of degenerative neuropathy, especially Alzheimer's disease.
Nº publicación: CN121003632A 25/11/2025
Solicitante:
THE SECOND AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV YUNNAN UROLOGY HOSPITAL YUNNAN LIVER SURGERY
\u6606\u660E\u533B\u79D1\u5927\u5B66\u7B2C\u4E8C\u9644\u5C5E\u533B\u9662\uFF08\u4E91\u5357\u7701\u6CCC\u5C3F\u4E13\u79D1\u533B\u9662\u3001\u4E91\u5357\u7701\u809D\u80C6\u80F0\u5916\u79D1\u533B\u9662\uFF09
Resumen de: CN121003632A
The invention provides application of chitosan oligosaccharide in treatment of Parkinson's disease. Specifically, the invention provides an application of chitosan oligosaccharide, the chitosan oligosaccharide is used for preparing a preparation or a composition, and the preparation or the composition is selected from one or more of the following applications: (a) inhibiting the expression of TSPO; (b) reducing the death of dopaminergic neurons; (c) increasing secretion of dopamine and metabolites thereof; (d) increasing the level of tyrosine hydroxylase (TH); (e) ameliorating dyskinesia; (f) treating and/or preventing Parkinson's disease (PD). The chitosan oligosaccharide disclosed by the invention can effectively relieve PD through a blood brain barrier.
BOPI
Sede Electrónica
